Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid's Xpert Flu/RSV Test Gets CE Mark

NEW YORK (GenomeWeb News) — Cepheid said today that it has received CE marking for Xpert Flu/RSV XC, an on-demand molecular test for determination of influenza A and B infection and differentiation of respiratory syncytial virus infection.

The new test runs on Cepheid's GeneXpert system, of which more than 7,000 are installed worldwide, Cepheid said.

"We employed a novel in silico approach to identify multiple complementary target segments to avoid the effects of seasonal genetic drift and to anticipate emerging novel influenza strains," Cepheid Chief Medical and Technology Officer David Persing said in a statement. "Though simple to perform, Xpert Flu/RSV XC is a highly multiplexed, state-of-the-art test for rapid and accurate detection and differentiation of Flu A, Flu B, and RSV infection."

Persing added that the test "may also become a valuable asset in efforts toward pandemic preparedness because it was designed from its inception to provide unprecedented coverage of avian influenza strains."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.